Pfizer's abnormally high yield seems more a symptom of all this negative sentiment than a red flag about the dividend's sustainability. Management just raised the quarterly dividend in December, and ...

Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Senator Ron Wyden (D-Ore.), a senior member of the Senate Finance Committee, accused Pfizer (PFE) of carrying out what he ...